• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性红斑狼疮疾病活动度评分(SLE-DAS)可实现临床缓解和疾病活动度分类的准确且用户友好的定义。

Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.

机构信息

Rheumatology Department, Centro Hospitalar de Leiria, Leiria, Portugal.

Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal.

出版信息

Ann Rheum Dis. 2021 Dec;80(12):1568-1574. doi: 10.1136/annrheumdis-2021-220363. Epub 2021 Aug 18.

DOI:10.1136/annrheumdis-2021-220363
PMID:34407927
Abstract

OBJECTIVES

There is an unmet need for accurate and user-friendly definitions of systemic lupus erythematosus (SLE) disease activity and remission. We aimed to derive and validate the SLE Disease Activity Score (SLE-DAS) definitions for disease activity categories and clinical remission state.

METHODS

Derivation was conducted at Padova Lupus Clinic (Italy). Validation was prospectively performed at Cochin Lupus Clinic (France) and by post hoc analysis of BLISS-76 trial. At each clinic, an expert classified patients in three categories: remission, mild or moderate/severe activity. The SLE-DAS cut-offs were derived using the receiver operating characteristic curve analysis in Padova cohort; its performance was assessed against expert classification in Cochin cohort and British Isles Lupus Assessment Group (BILAG) index in BLISS-76. Gold standard for clinical remission state was the fulfilment of Definition Of Remission In SLE. A Boolean and an index-based definitions of remission were sustained by chi-square automatic interaction detection algorithm. An SLE-DAS online calculator was developed and tested.

RESULTS

We included 1190 patients with SLE: 221 in the derivation cohort and 969 in the validation cohorts (150 from Cochin; 819 from BLISS-76). Derived cut-offs were: remission, SLE-DAS ≤2.08; mild activity, 2.08<SLE-DAS≤7.64; moderate/severe activity, SLE-DAS >7.64. Regarding validation in Cochin cohort, sensitivity and specificity are above 90%, 82% and 95% for remission, mild and moderate/severe activity, respectively. The SLE-DAS Boolean-based and index-based remission showed sensitivity of 100% and specificity above 97%.

CONCLUSION

The SLE-DAS is an accurate and easy-to-use tool for defining SLE clinical remission state and disease activity categories, validated against expert assessment and BILAG.

摘要

目的

目前仍需要准确且用户友好的系统性红斑狼疮(SLE)疾病活动度和缓解的定义。我们旨在制定和验证 SLE 疾病活动度评分(SLE-DAS)以定义疾病活动度类别和临床缓解状态。

方法

在意大利帕多瓦狼疮诊所进行了推导。在法国科钦狼疮诊所进行了前瞻性验证,并对 BLISS-76 试验进行了事后分析。在每个诊所,专家将患者分为三类:缓解、轻度或中度/重度活动。在帕多瓦队列中,使用接收者操作特征曲线分析得出 SLE-DAS 截断值;在科钦队列和英国狼疮评估组(BILAG)指数中评估其在 BLISS-76 中的表现。临床缓解状态的金标准是符合 SLE 缓解定义。缓解的布尔和基于指数的定义由卡方自动交互检测算法维持。开发并测试了一个 SLE-DAS 在线计算器。

结果

我们纳入了 1190 例 SLE 患者:推导队列 221 例,验证队列 969 例(科钦 150 例;BLISS-76 819 例)。推导的截断值为:缓解,SLE-DAS ≤2.08;轻度活动,2.08<SLE-DAS≤7.64;中度/重度活动,SLE-DAS >7.64。在科钦队列中进行验证时,缓解、轻度和中度/重度活动的敏感性和特异性均高于 90%,分别为 82%和 95%。SLE-DAS 基于布尔和基于指数的缓解具有 100%的敏感性和超过 97%的特异性。

结论

SLE-DAS 是一种准确且易于使用的工具,可用于定义 SLE 临床缓解状态和疾病活动度类别,经专家评估和 BILAG 验证。

相似文献

1
Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.系统性红斑狼疮疾病活动度评分(SLE-DAS)可实现临床缓解和疾病活动度分类的准确且用户友好的定义。
Ann Rheum Dis. 2021 Dec;80(12):1568-1574. doi: 10.1136/annrheumdis-2021-220363. Epub 2021 Aug 18.
2
Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort.基于 SLE-DAS 的低疾病活动状态定义:多中心真实队列中的推导和验证。
Rheumatology (Oxford). 2022 Aug 3;61(8):3309-3316. doi: 10.1093/rheumatology/keab895.
3
Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.系统性红斑狼疮疾病活动评分缓解和低疾病活动状态可区分药物和安慰剂,并改善健康相关生活质量。
Arthritis Care Res (Hoboken). 2024 Jun;76(6):788-795. doi: 10.1002/acr.25305. Epub 2024 Feb 29.
4
The effect of systemic lupus erythematosus (SLE) Disease Activity Score and SLE Disease Activity Index 2000-based remission states in patients with SLE on damage accrual.系统性红斑狼疮(SLE)疾病活动评分和基于 SLE 疾病活动指数 2000 的缓解状态对 SLE 患者的损害累积的影响。
Int J Rheum Dis. 2023 Dec;26(12):2509-2516. doi: 10.1111/1756-185X.14949. Epub 2023 Oct 24.
5
Trajectories of disease evolution upon treatment initiation in systemic lupus erythematosus: results from four clinical trials of belimumab.系统性红斑狼疮治疗起始后疾病演变轨迹:贝利尤单抗四项临床试验结果
Rheumatology (Oxford). 2025 May 1;64(5):2697-2705. doi: 10.1093/rheumatology/keae575.
6
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).SLE 缓解的框架:来自 SLE 缓解定义的大型国际工作组(DORIS)的共识结果。
Ann Rheum Dis. 2017 Mar;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.
7
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study.SLE-DAS 在评估系统性红斑狼疮患者疾病活动度中的价值:一项单中心回顾性研究。
Lupus Sci Med. 2024 Jun 10;11(1):e001196. doi: 10.1136/lupus-2024-001196.
8
Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials.在接受贝利尤单抗治疗的系统性红斑狼疮患者中达到缓解和低疾病活动度:五项随机临床试验汇总数据的事后分析。
Lancet Rheumatol. 2024 Nov;6(11):e751-e761. doi: 10.1016/S2665-9913(24)00162-0. Epub 2024 Aug 26.
9
Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria.使用贝利尤单抗治疗的系统性红斑狼疮患者的结局:基于英伦狼疮评估小组联合狼疮评估标准对五项III期临床试验进行的事后疗效分析
RMD Open. 2025 Apr 23;11(2):e005444. doi: 10.1136/rmdopen-2025-005444.
10
Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.肠溶型麦考酚钠与硫唑嘌呤治疗活动期系统性红斑狼疮的随机临床试验
Ann Rheum Dis. 2017 Sep;76(9):1575-1582. doi: 10.1136/annrheumdis-2016-210882. Epub 2017 Apr 27.

引用本文的文献

1
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial.用于治疗难治性系统性红斑狼疮的同种异体靶向CD19 T细胞:一项1期试验。
Nat Med. 2025 Aug 27. doi: 10.1038/s41591-025-03899-x.
2
Repeat renal biopsy findings in 82 lupus nephritis patients: a clinicopathological study.82例狼疮性肾炎患者重复肾活检结果:一项临床病理研究
Int J Clin Exp Pathol. 2025 Jul 15;18(7):364-374. doi: 10.62347/VFGO9374. eCollection 2025.
3
What's new in the assessment of lupus activity?狼疮活动评估有哪些新进展?
Rheumatol Adv Pract. 2025 May 26;9(3):rkaf062. doi: 10.1093/rap/rkaf062. eCollection 2025.
4
Serum glutathione reductase level as a disease activity biomarker in systemic lupus erythematosus: a single-centre preliminary study.血清谷胱甘肽还原酶水平作为系统性红斑狼疮疾病活动生物标志物的单中心初步研究。
Lupus Sci Med. 2025 Jun 24;12(1):e001593. doi: 10.1136/lupus-2025-001593.
5
SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies.系统性红斑狼疮疾病活动度评分(SLE-DAS)能够准确界定重症狼疮疾病活动:在阿尼鲁单抗II期和III期研究的一项事后分析中的推导与验证
Lupus Sci Med. 2025 May 16;12(1):e001499. doi: 10.1136/lupus-2025-001499.
6
Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus.系统性红斑狼疮疾病活动指数2000量表及系统性红斑狼疮疾病活动评分指数在日常实践中用于评估系统性红斑狼疮活动度的效用。
Reumatologia. 2024;62(3):187-195. doi: 10.5114/reum.2024.141291. Epub 2024 Jul 12.
7
Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study.SLE-DAS 在评估系统性红斑狼疮患者疾病活动度中的价值:一项单中心回顾性研究。
Lupus Sci Med. 2024 Jun 10;11(1):e001196. doi: 10.1136/lupus-2024-001196.
8
Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study.系统性红斑狼疮(SLE)患者妊娠及母婴结局的治疗变化:一项回顾性队列研究。
J Int Med Res. 2024 Jan;52(1):3000605231225349. doi: 10.1177/03000605231225349.
9
Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS.一种新的系统性红斑狼疮疾病活动度测量仪器的性能:SLE-DAS。
Medicina (Kaunas). 2023 Nov 29;59(12):2097. doi: 10.3390/medicina59122097.
10
Cardiac magnetic resonance assessment of cardiac involvement in autoimmune diseases.自身免疫性疾病心脏受累的心脏磁共振评估
Front Cardiovasc Med. 2023 Sep 22;10:1215907. doi: 10.3389/fcvm.2023.1215907. eCollection 2023.